Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 11/2012

01.11.2012 | ASSISTED REPRODUCTION TECHNOLOGIES

Metaphase II (MII) oocytes obtained at different time points in the same in vitro fertilization cycle

verfasst von: Hakan Cakmak, Victor Y. Fujimoto, A. Musa Zamah, Mitchell P. Rosen, Nam D. Tran, Marcelle I. Cedars, Paolo F. Rinaudo

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Excerpt

Oocyte maturation is required to complete meiosis and to produce a competent oocyte able to sustain embryo development, implantation and pregnancy. In humans, meiosis begins in the developing ovaries at 11–12 weeks of gestation [4]. The oocytes progress to diplotene stage of prophase I and then arrest until ovulation, an event that can occur decades later. Oocytes resume meiotic maturation in response to the midcycle luteinizing hormone (LH) surge. This final oocyte maturation can be induced medically with either human chorionic gonadotropin (hCG) or a gonadotropin-releasing hormone agonist (GnRHa). The former binds the LH receptor, while GnRHa promotes the release of endogenous gonadotropin stores from the hypophysis. …
Literatur
1.
Zurück zum Zitat Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grondahl ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum Reprod. 2006;21(8):2126–30.PubMedCrossRef Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grondahl ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum Reprod. 2006;21(8):2126–30.PubMedCrossRef
2.
Zurück zum Zitat Bomsel-Helmreich O, Huyen LV, Durand-Gasselin I, Salat-Baroux J, Antoine JM. Timing of nuclear maturation and cumulus dissociation in human oocytes stimulated with clomiphene citrate, human menopausal gonadotropin, and human chorionic gonadotropin. Fertil Steril. 1987;48(4):586–95.PubMed Bomsel-Helmreich O, Huyen LV, Durand-Gasselin I, Salat-Baroux J, Antoine JM. Timing of nuclear maturation and cumulus dissociation in human oocytes stimulated with clomiphene citrate, human menopausal gonadotropin, and human chorionic gonadotropin. Fertil Steril. 1987;48(4):586–95.PubMed
3.
Zurück zum Zitat Chen SL, Ye DS, Chen X, Yang XH, Zheng HY, Tang Y, He YX, Guo W (2012) Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Hum Reprod Chen SL, Ye DS, Chen X, Yang XH, Zheng HY, Tang Y, He YX, Guo W (2012) Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Hum Reprod
4.
Zurück zum Zitat De Felici M, Klinger FG, Farini D, Scaldaferri ML, Iona S, Lobascio M. Establishment of oocyte population in the fetal ovary: primordial germ cell proliferation and oocyte programmed cell death. Reprod Biomed Online. 2005;10(2):182–91.PubMedCrossRef De Felici M, Klinger FG, Farini D, Scaldaferri ML, Iona S, Lobascio M. Establishment of oocyte population in the fetal ovary: primordial germ cell proliferation and oocyte programmed cell death. Reprod Biomed Online. 2005;10(2):182–91.PubMedCrossRef
5.
Zurück zum Zitat Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren HG. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002;87(2):709–15.PubMedCrossRef Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren HG. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002;87(2):709–15.PubMedCrossRef
6.
Zurück zum Zitat Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab. 1983;57(4):792–6.PubMedCrossRef Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab. 1983;57(4):792–6.PubMedCrossRef
7.
Zurück zum Zitat Honnma H, Hashiba Y, Asada Y, Endo T. Failure of triggering oocyte maturation with a GnRH agonist in polycystic ovary syndrome: two case reports. Eur J Obstet Gynecol Reprod Biol. 2011;157(2):239–40.PubMedCrossRef Honnma H, Hashiba Y, Asada Y, Endo T. Failure of triggering oocyte maturation with a GnRH agonist in polycystic ovary syndrome: two case reports. Eur J Obstet Gynecol Reprod Biol. 2011;157(2):239–40.PubMedCrossRef
8.
Zurück zum Zitat Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod. 2009;24(10):2389–94.PubMedCrossRef Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod. 2009;24(10):2389–94.PubMedCrossRef
9.
Zurück zum Zitat Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril. 1991;56(2):213–20.PubMed Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril. 1991;56(2):213–20.PubMed
10.
Zurück zum Zitat McArdle CA, Franklin J, Green L, Hislop JN. Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol. 2002;173(1):1–11.PubMedCrossRef McArdle CA, Franklin J, Green L, Hislop JN. Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol. 2002;173(1):1–11.PubMedCrossRef
11.
Zurück zum Zitat Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsbøll S, Nielsen IK, Andersen AN. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a ‘standard' dose of 150 IU/day in ‘standard' patients undergoing IVF/ICSI treatment. Hum Reprod. 2003;18(11):2275–82.PubMedCrossRef Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsbøll S, Nielsen IK, Andersen AN. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a ‘standard' dose of 150 IU/day in ‘standard' patients undergoing IVF/ICSI treatment. Hum Reprod. 2003;18(11):2275–82.PubMedCrossRef
12.
Zurück zum Zitat Rosen MP, Shen S, Dobson AT, Rinaudo PF, McCulloch CE, Cedars MI. A quantitative assessment of follicle size on oocyte developmental competence. Fertil Steril. 2008;90(3):684–90.PubMedCrossRef Rosen MP, Shen S, Dobson AT, Rinaudo PF, McCulloch CE, Cedars MI. A quantitative assessment of follicle size on oocyte developmental competence. Fertil Steril. 2008;90(3):684–90.PubMedCrossRef
13.
Zurück zum Zitat Seibel MM, Smith DM, Levesque L, Borten M, Taymor ML. The temporal relationship between the luteinizing hormone surge and human oocyte maturation. Am J Obstet Gynecol. 1982;142(5):568–72.PubMed Seibel MM, Smith DM, Levesque L, Borten M, Taymor ML. The temporal relationship between the luteinizing hormone surge and human oocyte maturation. Am J Obstet Gynecol. 1982;142(5):568–72.PubMed
14.
Zurück zum Zitat Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Thomas S. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril. 2008;90(1):231–3.PubMedCrossRef Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Thomas S. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril. 2008;90(1):231–3.PubMedCrossRef
15.
Zurück zum Zitat Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguirre M, Hudson C. Efficacy of induced luteinizing hormone surge after "trigger" with gonadotropin-releasing hormone agonist. Fertil Steril. 2011;95(2):826–8.PubMedCrossRef Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguirre M, Hudson C. Efficacy of induced luteinizing hormone surge after "trigger" with gonadotropin-releasing hormone agonist. Fertil Steril. 2011;95(2):826–8.PubMedCrossRef
16.
Zurück zum Zitat Zelinski-Wooten MB, Lanzendorf SE, Wolf DP, Chandrasekher YA, Stouffer RL. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function. J Clin Endocrinol Metab. 1991;73(3):577–83.PubMedCrossRef Zelinski-Wooten MB, Lanzendorf SE, Wolf DP, Chandrasekher YA, Stouffer RL. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function. J Clin Endocrinol Metab. 1991;73(3):577–83.PubMedCrossRef
Metadaten
Titel
Metaphase II (MII) oocytes obtained at different time points in the same in vitro fertilization cycle
verfasst von
Hakan Cakmak
Victor Y. Fujimoto
A. Musa Zamah
Mitchell P. Rosen
Nam D. Tran
Marcelle I. Cedars
Paolo F. Rinaudo
Publikationsdatum
01.11.2012
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 11/2012
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-012-9852-5

Weitere Artikel der Ausgabe 11/2012

Journal of Assisted Reproduction and Genetics 11/2012 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.